We develop formulations for poorly water-soluble therapeutics
The majority of new chemical entities emerging from today's drug discovery pipelines are too poorly water-soluble to enable reproducible bioavailability and efficacy after oral intake. This greatly hinders drug development and ultimately prevents patients from accessing new treatments.
We focus solely on formulation design for poorly water-soluble small molecules. This technical focus enables us to develop better solutions faster than generalist CDMOs.
Low overhead
Our operational focus on early-phase formulation R&D allows us to work much more cost-effectively than manufacturing-CDMOs.
Dedication
Our founders are still closely involved in the day-to-day operations and ensure that every project is approached with diligence and dedication.